GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (LTS:0HX7) » Definitions » Total Payout Ratio

Adicet Bio (LTS:0HX7) Total Payout Ratio : 0.79 (As of Jun. 06, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Total Payout Ratio?

Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income.

Adicet Bio's current Total Payout Ratio is 0.79.


Adicet Bio Total Payout Ratio Historical Data

The historical data trend for Adicet Bio's Total Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Total Payout Ratio Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Payout Ratio
Get a 7-Day Free Trial - - 3.84 0.62 -

Adicet Bio Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Payout Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - 3.96

Competitive Comparison of Adicet Bio's Total Payout Ratio

For the Biotechnology subindustry, Adicet Bio's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adicet Bio's Total Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adicet Bio's Total Payout Ratio distribution charts can be found below:

* The bar in red indicates where Adicet Bio's Total Payout Ratio falls into.



Adicet Bio Total Payout Ratio Calculation

Total Payout Ratio is a measurement showing the proportion of earnings a company pays shareholders in the form of dividends and net stock repurchases.

Adicet Bio's Total Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 0 + 0) / -142.658
=0.00

Adicet Bio's Total Payout Ratio for the quarter that ended in Mar. 2024 is calculated as

Total Payout Ratio=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Net Income
=- (0 + 110.918 + 0) / -28.016
=3.96

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adicet Bio Total Payout Ratio Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Total Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicet Bio (LTS:0HX7) Business Description

Traded in Other Exchanges
Address
200 Clarendon Street, Floor 6, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The company operates and manages its business as one reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases.

Adicet Bio (LTS:0HX7) Headlines

No Headlines